Volume 2, Issue 4 (12-2020)
Tabari Biomed Stu Res J 2020, 2(4): 0-0 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Shamshirian A, Shamshirian D, Hosseinzadeh M H, Ebrahimzadeh M A. A Mini-Review and Perspective on Anti-hypoxic Hypothesis of COVID-19. Tabari Biomed Stu Res J 2020; 2 (4)
URL: http://tbsrj.mazums.ac.ir/article-1-3724-en.html
URL: http://tbsrj.mazums.ac.ir/article-1-3724-en.html
Amir Shamshirian1 
, Danial Shamshirian2 , Mohammad Hossein Hosseinzadeh3 , Mohammad Ali Ebrahimzadeh * 4
, Danial Shamshirian2 , Mohammad Hossein Hosseinzadeh3 , Mohammad Ali Ebrahimzadeh * 4
1- Department of Medical Laboratory Sciences, Student Research Committee, School of Allied Medical Science, Mazandaran University of Medical Sciences, Sari.
2- Gastrointestinal Cancer Research Center, Mazandaran University of Medical Sciences, Sari, Iran.
3- Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
4- Professor of Medicinal Chemistry, Pharmaceutical Sciences Research Center, Department of Medicinal Chemistry, School of Pharmacy, Mazandaran University of Medical Science, Sari, Iran.
2- Gastrointestinal Cancer Research Center, Mazandaran University of Medical Sciences, Sari, Iran.
3- Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
4- Professor of Medicinal Chemistry, Pharmaceutical Sciences Research Center, Department of Medicinal Chemistry, School of Pharmacy, Mazandaran University of Medical Science, Sari, Iran.
Abstract:
A novel coronavirus emerged in Wuhan, China; in December 2019 and has widely affected the global community. After months of extensive effort, much remains to be understood of the pathogenesis of Coronavirus Disease 2019 (COVID-19). The available evidence raises a critical question : Is COVID-19 a lung disorder leading to circulatory problems, or a systemic disorder that leads to lung problems?. If the latter scenario is correct, investigations on hypoxia conditions and the development of anti-hypoxia agents may lead to potential front-line treatments in combination with antivirals for hypoxemic COVID-19 patients. Hence, anti-hypoxic agents may become a potential part of combination therapy in hypoxemic respiratory failure and COVID-19.
Type of Study: Research (Original) |
Subject:
Infectious Diseases
Published: 2020/12/30 | ePublished: 2020/12/30
Published: 2020/12/30 | ePublished: 2020/12/30
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
